Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1967]

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

Phase Ib/II study of nivolumab in combination with azacytidine in patients with...

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid...

Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia ( Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK )

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Dr Max Topp - University of Wurzburg, Wurzburg, Germany

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )

Blood thinners a risk with cancer-associated venous thromboembolism

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...

Blood thinners a risk with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL

Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL ( Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA )

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )

ZUMA 1: CD19 CAR T cells for refractory NHL

Dr Yi Lin, Mayo Clinic - Rochester, MN, USA

$ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )$

Risk and benefit of anti-coagulants for elderly patients with cancer-associated...

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France

Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )

ZUMA1 trial of CD19 CAR T cells for aggressive NHL

Dr Yi Lin - Mayo Clinic, Rochester, USA

ZUMA1 trial of CD19 CAR T cells for aggressive NHL ( Dr Yi Lin - Mayo Clinic, Rochester, USA )

400mg imatinib as good as 800mg for 10 year CML survival

Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany

400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )

More from ecancer